Lazertinib at a glance
Medicine class
Third-generation EGFR tyrosine kinase inhibitor
Licensed role
First-line treatment of specified EGFR-mutated advanced non-small cell lung cancer, with amivantamab
Administration
Swallow the tablet whole; it may be taken with or without food
Important risks
Blood clots, lung inflammation, serious skin reactions and corneal inflammation require prompt recognition
What is Lazertinib used for?
The licensed product is used only with amivantamab.
First-line treatment of adults with advanced non-small cell lung cancer whose tumour has an EGFR exon 19 deletion or exon 21 L858R substitution mutation.
How does Lazertinib work?
Lazertinib blocks abnormal EGFR signalling that helps certain lung cancer cells grow. It preferentially inhibits common activating EGFR mutations and the T790M resistance mutation, with less activity against normal, wild-type EGFR.
Lazertinib preparations and strengths
Tablet
Route: Oral
Strengths: 80 mg, 240 mg
How to take Lazertinib
Follow the cancer team's prescription and do not stop treatment without speaking to them.
Swallow tablets whole with water; do not crush, split or chew them.
Take with or without food.
Follow the team's advice on sun protection and preventive skin care.
Lazertinib side effects
Common or expected effects
- Rash, itching and dry skin
- Nail problems
- Sore or inflamed mouth
- Tingling, numbness or altered sensation
- Tiredness
- Diarrhoea or constipation
- Reduced appetite, nausea or vomiting
- Muscle spasms
- Raised liver enzymes
- Fever
Get urgent medical advice
- Blood clot symptoms, including chest pain, breathlessness, rapid breathing or limb pain and swelling
- Possible lung inflammation: new or worsening breathlessness, cough or fever
- Severe, blistering, peeling or rapidly worsening skin reaction
- Eye pain, redness, light sensitivity or changes in vision
- Symptoms of a serious allergic reaction
Lazertinib in pregnancy
Lazertinib may harm an unborn baby and is generally avoided during pregnancy unless the specialist considers the benefit to outweigh the risk. Pregnancy status should be checked before treatment, and effective contraception is required during treatment and for 3 weeks afterwards. Contact the oncology team promptly if pregnancy occurs.
Lazertinib while breastfeeding
Do not breastfeed during treatment or for 3 weeks afterwards because transfer into breast milk and the risk to the child are unknown.
Lazertinib interactions
Give the oncology team and pharmacist a complete list of prescribed, non-prescribed and herbal products.
Strong CYP3A4 inducers, including rifampicin, carbamazepine and phenytoin
These can substantially reduce lazertinib exposure and should be avoided.
St John's wort
This may reduce lazertinib exposure and should be avoided.
CYP3A4 substrates with a narrow therapeutic index, including tacrolimus, ciclosporin, sirolimus and everolimus
Lazertinib may increase their exposure, so adverse-effect or concentration monitoring may be needed.
Common questions about Lazertinib
Answers are fully visible for fast scanning and source review.
What type of cancer is lazertinib used for?
It is licensed with amivantamab for adults receiving first-line treatment for advanced non-small cell lung cancer with an EGFR exon 19 deletion or exon 21 L858R mutation.
Why is an EGFR test needed?
Lazertinib targets specific abnormal forms of EGFR, so a validated test must confirm an eligible mutation before treatment starts.
Is lazertinib used on its own?
Its licence is for use with amivantamab, not as standalone treatment.
Can it be taken with food?
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.